Valeo Pharma Inc
TSX:VPH

Watchlist Manager
Valeo Pharma Inc Logo
Valeo Pharma Inc
TSX:VPH
Watchlist
Price: 0.045 CAD Market Closed
Market Cap: 4.4m CAD

Valeo Pharma Inc
Investor Relations

Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. The company is headquartered in Kirkland, Quebec and currently employs 100 full-time employees. The company went IPO on 2019-02-20. The firm acquires or in-licenses brand and hospital specialty products for sale in Canada. The firm is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The firm has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI).

Show more
Loading
VPH
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2024
Call Date
Sep 13, 2024
Q3 2024 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. Kyle Steiger
Senior VP & Chief Commercial Officer
No Bio Available
Mr. Al Moghaddam B. Com. Cma
Chief Executive Officer
No Bio Available
Mr. Pascal Tougas
Chief Financial Officer
No Bio Available
Mr. Guy-Paul Allard
VP of Legal Affairs & Corporate Secretary
No Bio Available
Mr. Jean Francois Fournier
Head of Ophthalmology Business Unit
No Bio Available

Contacts

Address
QUEBEC
Kirkland
16667 Hymus Blvd
Contacts
+15146938832.0
www.valeopharma.com